<?xml version='1.0' encoding='utf-8'?>
<document id="20489028"><sentence text="Effects of commonly administered agents and genetics on nebivolol pharmacokinetics: drug-drug interaction studies." /><sentence text="Drug interactions are a significant clinical concern, particularly in patients with conditions such as heart disease and hypertension, in whom coadministration of multiple drugs is common" /><sentence text=" Nebivolol is a selective Î²(1)-blocker with vasodilatory properties approved for the treatment of hypertension"><entity charOffset="1-10" id="DDI-PubMed.20489028.s3.e0" text="Nebivolol" /></sentence><sentence text=" Drug-drug interactions were investigated when nebivolol was coadministered to subjects classified as poor CYP2D6 metabolizers and extensive CYP2D6 metabolizers who were receiving other drugs commonly administered to patients with hypertension or compounds metabolized by cytochrome P450 (CYP) 2D6"><entity charOffset="47-56" id="DDI-PubMed.20489028.s4.e0" text="nebivolol" /></sentence><sentence text=" There were no drug-drug interactions when nebivolol was coadministered with hydrochlorothiazide, furosemide, ramipril, losartan, digoxin, or warfarin"><entity charOffset="43-52" id="DDI-PubMed.20489028.s5.e0" text="nebivolol" /><entity charOffset="77-96" id="DDI-PubMed.20489028.s5.e1" text="hydrochlorothiazide" /><entity charOffset="98-108" id="DDI-PubMed.20489028.s5.e2" text="furosemide" /><entity charOffset="110-118" id="DDI-PubMed.20489028.s5.e3" text="ramipril" /><entity charOffset="120-128" id="DDI-PubMed.20489028.s5.e4" text="losartan" /><entity charOffset="130-137" id="DDI-PubMed.20489028.s5.e5" text="digoxin" /><entity charOffset="142-150" id="DDI-PubMed.20489028.s5.e6" text="warfarin" /><pair ddi="false" e1="DDI-PubMed.20489028.s5.e0" e2="DDI-PubMed.20489028.s5.e0" /><pair ddi="false" e1="DDI-PubMed.20489028.s5.e0" e2="DDI-PubMed.20489028.s5.e1" /><pair ddi="false" e1="DDI-PubMed.20489028.s5.e0" e2="DDI-PubMed.20489028.s5.e2" /><pair ddi="false" e1="DDI-PubMed.20489028.s5.e0" e2="DDI-PubMed.20489028.s5.e3" /><pair ddi="false" e1="DDI-PubMed.20489028.s5.e0" e2="DDI-PubMed.20489028.s5.e4" /><pair ddi="false" e1="DDI-PubMed.20489028.s5.e0" e2="DDI-PubMed.20489028.s5.e5" /><pair ddi="false" e1="DDI-PubMed.20489028.s5.e0" e2="DDI-PubMed.20489028.s5.e6" /><pair ddi="false" e1="DDI-PubMed.20489028.s5.e1" e2="DDI-PubMed.20489028.s5.e1" /><pair ddi="false" e1="DDI-PubMed.20489028.s5.e1" e2="DDI-PubMed.20489028.s5.e2" /><pair ddi="false" e1="DDI-PubMed.20489028.s5.e1" e2="DDI-PubMed.20489028.s5.e3" /><pair ddi="false" e1="DDI-PubMed.20489028.s5.e1" e2="DDI-PubMed.20489028.s5.e4" /><pair ddi="false" e1="DDI-PubMed.20489028.s5.e1" e2="DDI-PubMed.20489028.s5.e5" /><pair ddi="false" e1="DDI-PubMed.20489028.s5.e1" e2="DDI-PubMed.20489028.s5.e6" /><pair ddi="false" e1="DDI-PubMed.20489028.s5.e2" e2="DDI-PubMed.20489028.s5.e2" /><pair ddi="false" e1="DDI-PubMed.20489028.s5.e2" e2="DDI-PubMed.20489028.s5.e3" /><pair ddi="false" e1="DDI-PubMed.20489028.s5.e2" e2="DDI-PubMed.20489028.s5.e4" /><pair ddi="false" e1="DDI-PubMed.20489028.s5.e2" e2="DDI-PubMed.20489028.s5.e5" /><pair ddi="false" e1="DDI-PubMed.20489028.s5.e2" e2="DDI-PubMed.20489028.s5.e6" /><pair ddi="false" e1="DDI-PubMed.20489028.s5.e3" e2="DDI-PubMed.20489028.s5.e3" /><pair ddi="false" e1="DDI-PubMed.20489028.s5.e3" e2="DDI-PubMed.20489028.s5.e4" /><pair ddi="false" e1="DDI-PubMed.20489028.s5.e3" e2="DDI-PubMed.20489028.s5.e5" /><pair ddi="false" e1="DDI-PubMed.20489028.s5.e3" e2="DDI-PubMed.20489028.s5.e6" /><pair ddi="false" e1="DDI-PubMed.20489028.s5.e4" e2="DDI-PubMed.20489028.s5.e4" /><pair ddi="false" e1="DDI-PubMed.20489028.s5.e4" e2="DDI-PubMed.20489028.s5.e5" /><pair ddi="false" e1="DDI-PubMed.20489028.s5.e4" e2="DDI-PubMed.20489028.s5.e6" /><pair ddi="false" e1="DDI-PubMed.20489028.s5.e5" e2="DDI-PubMed.20489028.s5.e5" /><pair ddi="false" e1="DDI-PubMed.20489028.s5.e5" e2="DDI-PubMed.20489028.s5.e6" /></sentence><sentence text=" Coadministration with fluoxetine (also metabolized by CYP2D6) in extensive CYP2D6 metabolizers impeded the apparent clearance of nebivolol"><entity charOffset="23-33" id="DDI-PubMed.20489028.s6.e0" text="fluoxetine" /><entity charOffset="130-139" id="DDI-PubMed.20489028.s6.e1" text="nebivolol" /><pair ddi="false" e1="DDI-PubMed.20489028.s6.e0" e2="DDI-PubMed.20489028.s6.e0" /><pair ddi="false" e1="DDI-PubMed.20489028.s6.e0" e2="DDI-PubMed.20489028.s6.e1" /></sentence><sentence text=" The authors conclude that nebivolol is safe and well tolerated regardless of genotype and type of medication coadministered"><entity charOffset="27-36" id="DDI-PubMed.20489028.s7.e0" text="nebivolol" /></sentence><sentence text="" /></document>